(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist
作者:Christian Thomsen、Rolf Hohlweg
DOI:10.1038/sj.bjp.0703661
日期:2000.11
Spiroxatrine was identified as a moderately potent (Ki=118 nM) but non‐selective agonist at the human nociceptin/orphanin FQ receptor, ORL1. This compound was subject to chemical modification and one of the resulting compounds, (8‐naphthalen‐1‐ylmethyl‐4‐oxo‐1‐phenyl‐1,3,8‐triaza‐spiro[4.5]dec‐3‐yl)‐acetic acid methyl ester (NNC 63‐0532) was shown to have high affinity for ORL1 (Ki=7.3 nM).
NNC 63‐0532 showed only moderate affinity for the following receptors (Ki values in parentheses): μ‐opioid (140 nM), κ‐opioid (405 nM), dopamine D2S (209 nM), dopamine D3 (133 nM) and dopamine D4.4 (107 nM) out of 75 different receptors, ion‐channels and transporters.
In functional assays, NNC 63‐0532 was shown to be an agonist at ORL1 (EC50=305 nM), a much weaker agonist at the μ‐opioid receptor (EC50>10 μM) and an antagonist or weak partial agonist at dopamine D2S (IC50=2830 nM).
Thus, NNC 63‐0532 is a novel non‐peptide agonist with ∼12 fold selectivity for ORL1 and may be useful for exploring the physiological roles of this receptor owing to its brain‐penetrating properties.
British Journal of Pharmacology (2000) 131, 903–908; doi:10.1038/sj.bjp.0703661
Spiroxatrine被鉴定为一种中等效力的( Ki = 118 nM)且非选择性的nociceptin/orphanin FQ受体(ORL1)激动剂。该化合物进行了化学修饰,其中一种产物,(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester(NNC 63-0532)显示出对ORL1的高亲和力(Ki = 7.3 nM)。
NNC 63-0532仅对以下受体显示出中等亲和力(括号中的Ki值):μ-阿片受体(140 nM),κ-阿片受体(405 nM),多巴胺D2S(209 nM),多巴胺D3(133 nM)和多巴胺D4.4(107 nM),在总共75种不同的受体、离子通道和转运体中。
在功能测定中,NNC 63-0532被证明是对ORL1的激动剂(EC50 = 305 nM),是对μ-阿片受体的较弱激动剂(EC50 > 10 μM),而对多巴胺D2S则是拮抗剂或弱的部分激动剂(IC50 = 2830 nM)。
因此,NNC 63-0532是一种新型的非肽类激动剂,对ORL1的选择性约为12倍,因其具有穿透脑的能力,可能有助于探索该受体的生理作用。
British Journal of Pharmacology (2000) 131, 903–908; doi:10.1038/sj.bjp.0703661